Compare Devon Energy Corp (DVN) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Devon Energy Corp vs Gilead Sciences, Inc. — how do they compare? Devon Energy Corp trades at $45.04 (market cap $49.94B), while Gilead Sciences, Inc. trades at $135.98 (market cap $168.35B). The key difference: Gilead Sciences, Inc. is far larger — about 3.4× Devon Energy Corp's market cap, and Devon Energy Corp pays the higher dividend (2.82%). Which is the better fit depends on your goals.
| DVN | GILD | |
|---|---|---|
Market Cap | $49.94B | $168.35B |
Sector | Energy | Health |
52-Week High | $52.07 | $155.80 |
52-Week Low | $31.74 | $110.56 |
Enterprise Value | $60.68B | $191.42B |
Dividend Yield | 2.82% | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Devon Energy (DVN) trades at $45.36, up 5.54% with strong technical momentum and bullish analyst sentiment. The company delivered robust Q2 2026 results, beating EPS estimates by 21% and revenue by 18%, while raising dividends 33% and accelerating debt reduction. Valuation remains attractive with P/E of 9.87 and EV/EBITDA of 6.89, supported by $1.7B Q2 free cash flow and $8B buyback authorization.
Outlook remains positive with merger synergies tracking ahead of schedule and 2026 revenue guidance of $19.7B. Key risks include oil price volatility and integration execution from the Coterra merger. With 71% analyst buy ratings and $61.91 consensus target representing 36% upside, DVN offers compelling value for energy investors seeking growth and shareholder returns.
Gilead Sciences (GILD) trades at $133.06, down slightly by 0.11% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 8% year-over-year, beating estimates, though a net loss of $6.75 per share resulted from acquisition-related costs. Analyst consensus is strongly bullish with a $151.22 price target, and recent news highlights robust HIV drug sales and pipeline progress.
The outlook for GILD is positive, driven by raised 2026 guidance and HIV franchise strength, but risks include patent cliffs by the mid-2030s and integration challenges from acquisitions. Investors should weigh the high valuation multiples against growth potential, with the stock offering upside if execution continues to exceed expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
